Clinical management of thrombosis in inherited factor VII deficiency: A description of two cases

• References

• 1 Acharya SS, Coughlin A, Dimichele DM. the North American Rare Bleeding Disorders Study Group.. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2: 248-256.
• 2 Cooper DN, Millar DS, Wacey A. et al. Inherited factor VII deficiency: molecular genetics and patho-physiology. Thromb Haemost 1997; 78: 151-160.
• 3 Mariani G, Herrmann FH, Dolce A. et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481-487.
• 4 Giansily-Blaizot M, Schved JF. Potential predictors of bleeding risk in inherited factor VII deficiency: Clinical, biological and molecular criteria. Thromb Haemost 2005; 94: 901-906.
• 5 Mariani G, Herrmann FH, Schulman S. et al. Thrombosis in inherited factor VII deficiency. J Thromb Haemost 2004; 1: 2153-2158.
• 6 Girolami A, Ruzzon E, Tezza F. et al. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia 2006; 12: 345-351.
• 7 Marty S, Barro C, Chatelain B. et al. The paradoxical association between inherited factor VII deficiency and venous thrombosis. Haemophilia 2008; 14: 564-570.
• 8 Barcellona D, Vannini ML, Fenu L. et al. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?. Thromb Haemost 1998; 80: 899-902.
• 9 D’Angelo A, Della VP, Crippa L. et al. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. Haematologica 2002; 87: 1074-1080.
• 10 Watala C, Golanski J, Kardas P. Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients. Thromb J 2003; 1: e7.
• 11 Giansily-Blaizot M, Verdier R, Biron-Adreani C. et al. Study group of FVII deficiency.. Analysis of biological phenotypes from 42 patients with inherited factor VII deficiency: can biological tests predict the bleeding risk?. Haematologica 2004; 89: 704-709.
• 12 Baltodano LE, Mungall DR, Watson DD. Management of a patient with atrial fibrillation and factor VII deficiency. Ann Pharmacother 1998; 32: 1251-1252.
• 13 Younger JR, McHenry JG. Visually disabling non-traumatic orbital hemorrhage in an anticoagulated patient with factor VII deficiency. J Neuro-Ophthalmol 2006; 26: 76-77.
• 14 Barnett JM, Demel KC, Mega AE. et al. Lack of bleeding in patients with severe factor VII deficiency. Am J Hematol 2005; 78: 134-137.
• 15 Bolt G, Steenstrup TD, Kristensen C. All post-translational modifications except propeptide cleavage are required for optimal secretion of coagulation factor VII. Thromb Haemost 2007; 98: 988-997.
• 16 Presnell SR, Stafford DW. The vitamin K-dependent carboxylase. Thromb Haemost 2002; 87: 937-946.
• 17 Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.